Charles Schwab Investment Management Inc. Decreases Stake in Organogenesis $ORGO

Key Points

• Charles Schwab Investment Management Inc. has decreased its stake in Organogenesis by 9.8%, holding approximately 0.66% of the company’s stock after selling 90,614 shares in the first quarter.
• Institutional investors have varied positions in Organogenesis, with Wealth Enhancement Advisory Services LLC growing its stake by 10.8% and other firms like Wells Fargo increasing theirs by 29.6%.
• Organogenesis reported a quarterly loss of ($0.09) EPS, missing estimates, and has set a fiscal year 2025 guidance with an average forecast of ($0.07) EPS.

Charles Schwab Investment Management Inc. trimmed its holdings in Organogenesis (NASDAQ:ORGO - Free Report) by 9.8% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 835,046 shares of the company's stock after selling 90,614 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.66% of Organogenesis worth $3,607,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its holdings in Organogenesis by 10.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock valued at $187,000 after acquiring an additional 4,239 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Organogenesis by 29.6% during the fourth quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock valued at $133,000 after purchasing an additional 9,464 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Organogenesis by 18.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock worth $8,925,000 after purchasing an additional 442,772 shares during the last quarter. Squarepoint Ops LLC increased its stake in shares of Organogenesis by 53.2% in the fourth quarter. Squarepoint Ops LLC now owns 126,791 shares of the company's stock worth $406,000 after buying an additional 44,051 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in Organogenesis by 255.1% during the 4th quarter. Mackenzie Financial Corp now owns 76,353 shares of the company's stock valued at $244,000 after buying an additional 54,850 shares during the last quarter. Institutional investors own 49.57% of the company's stock.

Wall Street Analyst Weigh In

ORGO has been the topic of a number of analyst reports. Cantor Fitzgerald boosted their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. BTIG Research reissued a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Organogenesis has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Insiders Place Their Bets

In other news, insider Lori Freedman acquired 9,022 shares of the firm's stock in a transaction on Friday, June 6th. The stock was acquired at an average price of $2.99 per share, for a total transaction of $26,975.78. Following the completion of the acquisition, the insider owned 846,459 shares in the company, valued at $2,530,912.41. This trade represents a 1.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.00% of the stock is currently owned by insiders.

Organogenesis Price Performance

ORGO stock traded up $0.10 during trading on Wednesday, reaching $5.00. The company had a trading volume of 201,186 shares, compared to its average volume of 1,395,168. Organogenesis has a 52 week low of $2.45 and a 52 week high of $6.71. The business has a 50 day moving average of $4.53 and a 200 day moving average of $4.20. The company has a market cap of $633.79 million, a P/E ratio of -35.53 and a beta of 1.75.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The firm had revenue of $101.01 million for the quarter, compared to analysts' expectations of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Research analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.